Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.35 |
| ▸ | F7 | P08709 | 13/20 | 0.34 |
| ▸ | F3 | P13726 | 13/20 | 0.34 |
| ▸ | F10 | P00742 | 8/20 | 0.33 |
| ▸ | F2 | P00734 | 7/20 | 0.33 |
| ▸ | F11 | P03951 | 4/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2914276 | 0.95 | F7 (0.37) | NR1H4F7F3F10F2 | |
| SCHEMBL4330201 | 0.92 | NR1H4 (0.37) | NR1H4F7F3F10F2 | |
| SCHEMBL2852068 | 0.88 | NR1H4 (0.35) | NR1H4F7F3F10F2 | |
| SCHEMBL2914274 | 0.86 | F7 (0.38) | NR1H4F7F3F10F2 | |
| SCHEMBL2916735 | 0.86 | F7 (0.35) | NR1H4F7F3F10F2 | |
| SCHEMBL2912587 | 0.86 | F7 (0.39) | NR1H4F7F3F10F2 | |
| SCHEMBL4761375 | 0.86 | NR1H4 (0.37) | NR1H4F7F3F10F2 | |
| SCHEMBL4332034 | 0.86 | F7 (0.37) | NR1H4F7F3F10F2 | |
| SCHEMBL2908391 | 0.85 | F7 (0.34) | NR1H4F7F3F10F2 | |
| SCHEMBL2915397 | 0.83 | F7 (0.42) | F7F3F10F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | NR1H4 3807/4885F7 35/4885F3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.